Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB

Trial Profile

Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Miglustat (Primary) ; Enzyme replacements
  • Indications Gaucher's disease type III
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
    • 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top